Donlar Announces Order Doubling Current Revenues for Oil Field Application Products.

Business Editors

BEDFORD PARK, Ill.--(BUSINESS WIRE)--Dec. 10, 2001

Donlar Biosyntrex Corporation (OTC: DBSY), a world leader in green chemistry, products and technology, today announced the receipt of orders for more than two million pounds of biodegradable thermal polyaspartate (TPA) products to be delivered over the twelve months beginning January, 2002. The Company further expects that this increased demand should result in a continuation of growth in biopolymer sales.

The receipt of these orders represents a doubling in the Company's shipments to the off-shore oilfield market. For the first nine months ended September 30, 2001, Donlar reported total sales of $1.7 million. The Company believes the current sales potential for its environmentally safe products in oilfield applications may exceed $600 million worldwide annually.

Larry Koskan, President and CEO of Donlar said, "We are excited to be starting the new year off with a very high level of assurance that 2002 will represent another record year in Company product sales. We expect to book additional orders of biopolymer products for industrial, agricultural and consumer markets throughout the next year."

About Donlar

Donlar Biosyntrex Corporation is at the forefront of providing a new class of protein biopolymers that help customers by providing solutions while satisfying environmental concerns for the creation of non-toxic products for a wide range of industrial, agricultural and consumer markets. The Company's non-hazardous, non-toxic, hypoallergenic, environmentally friendly and biodegradable thermal polyaspartate (TPA) biopolymers are protected by 140 Company owned patents. The Company's initial applications for its products include the markets of oil field operations, fertilizers, detergents and water treatment. Donlar Biosyntrex also markets a patented natural whey protein used in nutraceutical supplement markets and the Mountain Lift(TM) energy bar. Donlar's protein biopolymers are manufactured in its 50,000 square foot facility located in Peru, Illinois. (www.donlar.com)

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results could differ materially from those projected in the forward-looking statements, which involve a number of risks and uncertainties. The contents of this release should be considered in conjunction with the risk factors in Donlar Biosyntrex's most recent filings with the Securities and Exchange Commission on Forms 10-QSB and 10-KSB and current reports on Form 8-K.